Vaniprevir
Alternative Names: MK-7009; VanihepLatest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Class Antivirals; Macrocyclic compounds; Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 30 Sep 2014 Registered for Hepatitis C (Combination therapy) in Japan (PO) - First global approval
- 31 Mar 2014 Merck & Co. completes a phase III trial for Hepatitis C (combination therapy, treatment naive) in Japan (NCT01370642)
- 14 Jan 2014 Preregistration for Hepatitis C (combination therapy) in Japan (PO)